National Institutes of Health to evaluate Enesi Pharma’s Implavax®-enabled flu vaccines
pharmafile | October 19, 2021 | News story | Manufacturing and Production |
Enesi Pharma, a pioneering biotechnology company, has entered an agreement with the US National Insitutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). This new study will test a pandemic flu vaccine, enabled by ImplaVax® technologies.
Enesi Pharma develops innovative vaccination products to treat infectious diseases and emergent threat pathogens, and has a proven track record of the successful development and commercialisation of innovative vaccination products. Enesi develop groundbreaking, ImplaVax-enabled solid-dose, needle-free delivery, and multi-use (up to 1000 times) vaccines. The ImplaVax system is a formulation applicable across all vaccine formats.
Enesi are committed to making positive differences to global healthcare, including improved access to medicine, better health outcomes, and reduced environmental footprint. The ImplaVax system reduces waste, enables easier vaccine administration, and allows for easier mass-immunisation, all vital to the treatment of highly infectious and emergent diseases. NIAID-funded contractors will test the ImplaVax formulation in animal model challenge studies against flu viruses.
The company have already successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccines. NIAID continues to prepare for pandemic influenza and emerging strains of avian influenza, including the H7N9 virus. They also plan to develop flu vaccines capable of providing durable protection against multiple strains of influenza. Other Enesi projects include the development of vaccination products for measles-Rubella, HPV, and HIV, alongside emergent threat pathogens.
David Hipkiss, CEO and Director of Enesi Pharma, has commented:
“We are excited to expand upon our successful work with BARDA and with the assistance of NIAID advance our understanding and future use of ImplaVax in this critical area of international importance.”
Ana Ovey
